AIM-HI Accelerator Fund, the translational research affiliate of the National Foundation for Cancer Research (NFCR), has introduced a first-of-its-kind award to elevate the impact of women leaders in cancer research.
The inaugural recipient of this exciting and unparalleled award is the distinguished Anna D. Barker, Ph.D., Chief Strategy Officer at the Lawrence J. Ellison Institute for Transformative Medicine.
Anna D. Barker, Ph.D., is an accomplished researcher who has led landmark projects such as The Cancer Genome Atlas. Barker is also an early supporter of GBM AGILE, the adaptive clinical trial challenging how we evaluate cancer treatments for glioblastoma.
The Beacon Award for Women Leaders in Oncology aims to bridge the funding gap in translating innovations from the lab to the clinic and amplify women leaders and entrepreneurs. Like NFCR, AIM-HI addresses the unmet needs of the cancer community, and alleviating the inequity of support received by women entrepreneurs is a cornerstone of the Beacon Award’s mission.
NFCR will honor Anna Barker at the 2022 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship. Join us to celebrate Dr. Barker and other leaders in healthcare. Secure your ticket today at www.nfcr.org/Summit22!
NFCR is proud to be a founding partner of the AIM-HI Accelerator Fund, which continues to improve neglected areas of cancer research, namely the ‘Valley of Death‘ The Beacon Award is among the newest ways the organization serves its mission by amplifying the significant contributions of Women in Oncology.
Please join us in congratulating Anna D. Barker, Ph.D.!
Read more about Dr. Barker’s significant contributions and the Beacon Award on aim-hiaccelerator.org.